K. Hosszu

发表

C1q as an autocrine and paracrine regulator of cellular functions.

E. Peerschke, B. Ghebrehiwet, K. Hosszu, 2017, Molecular immunology.

Targeting gC1qR domains for therapy against infection and inflammation.

J. Jesty, E. Peerschke, Nithin Tumma, 2013, Advances in experimental medicine and biology.

Soluble gC1qR Is an Autocrine Signal That Induces B1R Expression on Endothelial Cells

U. Kishore, D. Galanakis, E. Peerschke, 2014, The Journal of Immunology.

Induces B1R Expression on Endothelial Cells Soluble gC1qR Is an Autocrine Signal That

D. Galanakis, E. Peerschke, D. Habiel, 2014 .

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

Y. Taur, G. Block, M. V. D. van den Brink, 2022, medRxiv.

GPRC5D-Targeted CAR T Cells for Myeloma.

S. Devlin, A. Lesokhin, V. Bermudez, 2022, The New England journal of medicine.

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

S. Devlin, A. Lesokhin, V. Bermudez, 2021, Blood.

A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression

M. V. D. van den Brink, A. Lesokhin, M. Mayerhoefer, 2022, Blood.

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

M. Dhodapkar, P. Westervelt, M. Perales, 2023, eClinicalMedicine.

Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization

S. Nierkens, J. Boelens, Kinga K. Hosszu, 2020, Frontiers in Pediatrics.

Developing a membrane-proximal CD33-targeting CAR T cell

R. Brentjens, A. Daniyan, K. Hosszu, 2024, Journal for ImmunoTherapy of Cancer.

Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.

N. Shukla, A. Scaradavou, J. Boelens, 2024, Cytotherapy.

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

E. Drill, Anita Kumar, A. Noy, 2024, Nature medicine.

MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT

Anastasia I. Kousa, A. Bush, M. Perales, 2022, Science Translational Medicine.